Plain-English translation of NCT06581562 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Rheumatoid Arthritis research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether , a new medication, works better when combined with (a drug already approved for treating certain autoimmune diseases) in patients with rheumatoid arthritis, pemphigus vulgaris, lupus, or granulomatosis with polyangiitis. Researchers want to understand if this combination is safe and more effective than current treatments. The study will involve about 30 patients divided into four groups, one for each condition.
Some patients with autoimmune diseases don't respond well enough to alone or experience side effects. This trial explores whether adding to the existing treatment can improve outcomes and help more patients control their disease.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be placed into one of four groups based on your diagnosis. You will receive and the new medication according to a study schedule. Throughout the trial, you will have regular clinic visits for blood work, heart imaging, lung function tests, and physical exams to monitor how you are responding and check for any side effects. The study team will work with you to gradually reduce your steroid doses as your disease improves.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States